With the aim to support Taiwan's biotech start-up companies in a more comprehensive way, Development Center for Biotechnology (DCB) operating NanKang Biotech Incubation Center (NBIC) established Digital Health Accelerator Program focusing on biomedical related fields in 2018. In less than two years, AllBio Science which participated in the first Digital Health Accelerator Program has obtained fruitful research and development results. In the face of global anti-epidemic demand in 2020 and the recent crisis of a re-emergence of the pandemic, TUL Corporation's subsidiary Technology Created Medicine Corporation (TCMC) successfully drew up a three-stage epidemic prevention strategy through cooperation with the cross-funded communications and biomedical industries. Through a three-stage strategy of phases, regions and purposes, TCMC independently developed antibody and antigen rapid screening reagent. This will play a key role in the prevention of COVID-19 pandemic, allowing suspected infections to be effectively detected through rapid screening and reducing the spread of the epidemic while tracing the source of the infection.

The Digital Health International Accelerator established by DCB is the first professional accelerator in Taiwan that focuses on the biotechnology and medical field. It not only assists Taiwan's biotechnology start-ups and teams to link domestic and foreign industrial resources, but also accelerates the link between Taiwan's innovation and the international market. AllBio Science is the start-up cultivated by DCB Digital Health Accelerator in the first year. With the accelerator's cultivation mechanism, it assisted AllBio Science in linking up with domestic and foreign industry contacts in a short time, and successfully introduced TUL Corporation's subsidiary TCMC to convey cooperation. The program also led AllBio Science to Boston, a major biotechnology innovation city, for international innovation exchanges. AllBio Science was also selected as one of the Top 3 enterprises of DCB Digital Health International Accelerator 2018 because of its mastery of core technologies in the fields of gene synthesis, protein expression and customized antibodies. In addition, DCB has also continued to guide AllBio Science in connecting important domestic and foreign venture capital, receiving sufficient funds for its operations, and promoted the development of a number of important new immunology products and services,” said Chung-hsiun Wu, CEO of DCB.

The first wave of AllBio Science's epidemic prevention is the rapid screening test reagent for IgG & IgM antibodies. The result can be delivered after 5 to 8 minutes with only a small amount of blood sample to detect the IgG and IgM in the body of COVID-19 infected patients. It is suitable for quickly providing a reference basis for immune system changes during isolation. Through the IRB clinical trial plan, which provided 30 positive and 75 negative serum samples for comparison tests from the National Health Research Institutes Biobank, the test results showed that the positive agreement rate and the negative agreement rate are both 100%. At present, in addition to having obtained the EU CE certification, it has also been approved to be manufactured by Taiwan Food and Drug Administration's epidemic prevention project, and TCMC is entrusted with overseas market sales,” said Chang-wei Li, CEO of AllBio Science.

To increase the comprehensiveness of the rapid screening test, AllBio Science has simultaneously developed the "COVID-19 Antigen Rapid Screening Test Reagent" as the second wave of epidemic prevention. By collecting samples of the nasal mucosa, result can also be delivered after 5 to 8 minutes to detect the presence of viral antigens on the nasal mucosa of the infected person. For sites that urgently need a large number of screenings, such as campuses, factories, airports, etc., the time and labor costs for sending samples to the laboratory can be rapidly reduced, and can be used as the basis for the initial PCR screening of infected persons. The product has entered the pre-review stage of the Food and Drug Administration, and can apply for further approval for manufacturing license after third-party verification data with medical institution is released.

Finally, the third wave of epidemic prevention uses a multiple detection platform, combined with an AllCHECK electronic chip device, and integrates AI smart interpretation and cloud systems. It is a global original "full quantitative" rapid screening detection system. It only takes 5 minutes to detect new coronavirus nucleic acid, antigen or antibody values in human body. It can also be used to analyze the degree of infection based on the values, to exclude false positive and false negative test results that cannot be judged by the naked eyes. Whether the patient has recently been infected with the disease or has recovered with antibodies can be accurately judged. It is an important tool for doctors’ and physicians' follow-up diagnosis. In the future, we look forward to using these three waves to provide a more complete solution for global epidemic prevention.

DCB introduced Digital Health Accelerator to discover and successfully coach AllBio Science. The COVID-19 epidemic prevention has rapidly increased the global rapid screening test market by billions of dollars. AllBio Science's reagent research and development combined with TCMC's overseas market expansion can contribute to the global epidemic prevention and become a model for the creation and cultivation of DCB.

About TUL

Established in 1997, TUL Corporation has dedicated its brand marketing and services in offering the ultimate total technology solutions. The current product lineup includes high-end gaming graphics cards, graphics cards dedicated for industrial control, SoC motherboards and systems, and FPGA solutions. Using the renowned brand name PowerColor as a represent of the world’s leading supplier for graphics cards, TUL also becomes the top 3 manufacturers of AMD graphics cards. In addition, TUL Embedded provides customized services to produce graphics cards dedicated for industrial control which have been adopted by major industrial computer companies. For more information, please visit http://www.tul.com.tw

Contact Us:

TUL Corp.

周忠信 Charles Chou

Tel: ＋886-2-86983000ext232

Fax: ＋886-2-86983456

Email: charles_chou@tul.com.tw